Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 652

1.

Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.

Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM.

Ann Rheum Dis. 2019 Oct;78(10):1333-1338. doi: 10.1136/annrheumdis-2019-215304. Epub 2019 Jun 13.

PMID:
31196844
2.

A global perspective on the challenges and opportunities in learning about rheumatic and musculoskeletal diseases in undergraduate medical education : White paper by the World Forum on Rheumatic and Musculoskeletal Diseases (WFRMD).

Al Maini M, Al Weshahi Y, Foster HE, Chehade MJ, Gabriel SE, Saleh JA, Al Wahshi H, Bijlsma JWJ, Cutolo M, Lakhanpal S, Venkatramana M, Pineda C, Woolf AD.

Clin Rheumatol. 2019 May 24. doi: 10.1007/s10067-019-04544-y. [Epub ahead of print] Review.

PMID:
31127461
3.

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review.

Verhoeven MMA, Welsing PMJ, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Tekstra J, Jacobs JWG.

Curr Rheumatol Rep. 2019 Apr 23;21(6):24. doi: 10.1007/s11926-019-0821-1. Review.

4.

Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review.

Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, van Laar JM, Lafeber FPJG, Bijlsma JWJ, Jacobs JWG.

Joint Bone Spine. 2019 Apr 11. pii: S1297-319X(19)30054-5. doi: 10.1016/j.jbspin.2019.04.002. [Epub ahead of print]

PMID:
30981868
5.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

6.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

7.

The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group.

Oude Voshaar MAH, Das Gupta Z, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, Curtis JR, Ellis B, Ernestam S, Gossec L, Hale C, Hornjeff J, Leung KYY, Lidar M, Mease P, Michaud K, Mody GM, Ndosi M, Opava CH, Pinheiro GRC, Salt M, Soriano ER, Taylor WJ, Voshaar MJH, Weel AEAM, de Wit M, Wulffraat N, van de Laar MAFJ, Vonkeman HE.

Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23799. [Epub ahead of print]

8.

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.

Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2.

9.

Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis.

Mahler EAM, den Broeder AA, den Broeder N, Bijlsma JWJ, Snijders GF, van den Hoogen FHJ, van den Ende CHM.

Clin Exp Rheumatol. 2019 May-Jun;37(3):414-421. Epub 2018 Sep 17.

PMID:
30299244
10.

Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.

Abhishek A, Iagnocco A, Bijlsma JWJ, Doherty M, Lioté F.

RMD Open. 2018 Sep 21;4(2):e000743. doi: 10.1136/rmdopen-2018-000743. eCollection 2018.

11.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
12.

RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers.

Cuppen BVJ, Rossato M, Fritsch-Stork RDE, Concepcion AN, Linn-Rasker SP, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Radstake TR; all SRU investigators.

Expert Rev Clin Immunol. 2018 Jul;14(7):623-633. doi: 10.1080/1744666X.2018.1480937. Epub 2018 Jun 6.

PMID:
29808722
13.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
14.

Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):976-983. Epub 2018 May 8.

15.

Disease activity and dropout in young persons with juvenile idiopathic arthritis in transition of care: a longitudinal observational study.

van Pelt PA, Dolhain RJEM, Kruize AA, Ammerlaan JJW, Hazes JW, Bijlsma JWJ, Wulffraat NM.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):163-168. Epub 2018 Jan 31.

PMID:
29461957
16.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
17.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
18.

Response to eLetter: 'Discussion of methotrexate dosage' by Maguire et al.

Safy M, Jacobs JWG, Ijff ND, Bijlsma JWJ, van Laar JM, de Hair MJH; Society for Rheumatology Research Utrecht (SRU).

Ann Rheum Dis. 2018 Aug;77(8):e48. doi: 10.1136/annrheumdis-2017-212380. Epub 2017 Oct 9. No abstract available.

PMID:
28993345
19.

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.

Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases.

Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2.

PMID:
28866648
20.

Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases.

Mahler EAM, Boers N, Bijlsma JWJ, van den Hoogen FHJ, den Broeder AA, van den Ende CHM.

J Rheumatol. 2018 Jan;45(1):122-127. doi: 10.3899/jrheum.170181. Epub 2017 Aug 15.

PMID:
28811352
21.

Will we ever have better glucocorticoids?

Buttgereit F, Bijlsma JWJ, Strehl C.

Clin Immunol. 2018 Jan;186:64-66. doi: 10.1016/j.clim.2017.07.023. Epub 2017 Jul 27.

PMID:
28757452
22.

Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Mokry M, Borm MEA, Pethö-Schramm A, van Laar JM, Bijlsma JWJ, Lafeber FPJ.

Arthritis Res Ther. 2017 Jul 20;19(1):170. doi: 10.1186/s13075-017-1378-x.

23.

A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement.

Rubbert-Roth A, Jacobs JWG, Bijlsma JWJ, Welsing PMJ.

Ann Rheum Dis. 2018 Jul;77(7):1085-1086. doi: 10.1136/annrheumdis-2017-211485. Epub 2017 Jun 23. No abstract available.

PMID:
28646081
24.

Managing rheumatic and musculoskeletal diseases - past, present and future.

Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB.

Nat Rev Rheumatol. 2017 Jul;13(7):443-448. doi: 10.1038/nrrheum.2017.95. Epub 2017 Jun 15. Review.

PMID:
28615732
25.

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.

Bouman CA, van Herwaarden N, van den Hoogen FH, Fransen J, van Vollenhoven RF, Bijlsma JW, Maas AV, den Broeder AA.

Ann Rheum Dis. 2017 Oct;76(10):1716-1722. doi: 10.1136/annrheumdis-2017-211169. Epub 2017 Jun 12.

PMID:
28606961
26.

Glucocorticoids in rheumatoid arthritis: the picture is shaping up.

Buttgereit F, Bijlsma JW.

Ann Rheum Dis. 2017 Nov;76(11):1785-1787. doi: 10.1136/annrheumdis-2017-211187. Epub 2017 May 4. No abstract available.

PMID:
28473424
27.

EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis.

Sakellariou G, Conaghan PG, Zhang W, Bijlsma JWJ, Boyesen P, D'Agostino MA, Doherty M, Fodor D, Kloppenburg M, Miese F, Naredo E, Porcheret M, Iagnocco A.

Ann Rheum Dis. 2017 Sep;76(9):1484-1494. doi: 10.1136/annrheumdis-2016-210815. Epub 2017 Apr 7.

28.

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X.

Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.

PMID:
28363827
29.

The most important needs and preferences of patients for support from health care professionals: A reflective practice on (transitional) care for young adults with Juvenile Idiopathic Arthritis.

Ammerlaan JW, van Os-Medendorp H, de Boer-Nijhof NC, Prakken B, Bijlsma JWJ, Kruize AA.

Patient Educ Couns. 2017 Oct;100(10):1961-1964. doi: 10.1016/j.pec.2017.03.018. Epub 2017 Mar 12.

PMID:
28363359
30.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM.

Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15. Review.

PMID:
28298374
31.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R.

Ann Rheum Dis. 2017 Jun;76(6):1113-1136. doi: 10.1136/annrheumdis-2016-210713. Epub 2017 Mar 10. Review.

PMID:
28283512
32.

Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment.

Cuppen BV, Pardali K, Kraan MC, Marijnissen AC, Yrlid L, Olsson M, Bijlsma JW, Lafeber FP, Fritsch-Stork RD.

Rheumatol Int. 2017 Apr;37(4):531-536. doi: 10.1007/s00296-017-3653-1. Epub 2017 Jan 28.

33.

Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study.

Amann J, Wessels AM, Breitenfeldt F, Huscher D, Bijlsma JWJ, Jacobs JWG, Buttgereit F.

Clin Exp Rheumatol. 2017 May-Jun;35(3):471-476. Epub 2017 Jan 15.

PMID:
28094753
34.

Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.

Strehl C, van der Goes MC, Bijlsma JW, Jacobs JW, Buttgereit F.

Expert Opin Investig Drugs. 2017 Feb;26(2):187-195. doi: 10.1080/13543784.2017.1276562. Epub 2017 Jan 3. Review.

PMID:
28043173
35.

"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements.

Palmowski Y, Buttgereit T, Dejaco C, Bijlsma JW, Matteson EL, Voshaar M, Boers M, Buttgereit F.

Arthritis Care Res (Hoboken). 2017 Aug;69(8):1134-1141. doi: 10.1002/acr.23185. Epub 2017 Jul 10. Review. Erratum in: Arthritis Care Res (Hoboken). 2018 Jan;70(1):144.

36.

Erratum to: Rheumatology training experience across Europe: analysis of core competences.

Sivera F, Ramiro S, Cikes N, Cutolo M, Dougados M, Gossec L, Kvien TK, Lundberg IE, Mandl P, Moorthy A, Panchal S, da Silva JA, Bijlsma JW; Working Group on Training in Rheumatology across Europe.

Arthritis Res Ther. 2016 Dec 19;18(1):300. No abstract available.

37.

Preferences and needs of patients with a rheumatic disease regarding the structure and content of online self-management support.

Ammerlaan JW, van Os-Medendorp H, de Boer-Nijhof N, Maat B, Scholtus L, Kruize AA, Bijlsma JW, Geenen R.

Patient Educ Couns. 2017 Mar;100(3):501-508. doi: 10.1016/j.pec.2016.10.009. Epub 2016 Oct 13.

PMID:
27776789
38.

Can adverse effects of glucocorticoid therapy be prevented and treated?

van der Goes MC, Strehl C, Buttgereit F, Bijlsma JW, Jacobs JW.

Expert Opin Pharmacother. 2016 Nov;17(16):2129-2133. Epub 2016 Sep 20. No abstract available.

PMID:
27590884
39.

Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.

Cuppen BV, Jacobs JW, Ter Borg EJ, Marijnissen AC, Bijlsma JW, Lafeber FP, van Laar JM; all SRU investigators.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):221-228. Epub 2016 Oct 7.

40.

Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment.

Fu J, Cuppen BV, Welsing PM, van Wietmarschen H, Harms AC, Berger R, Koval S, Fritsch-Stork RD, Bijlsma JW, Hankemeier T, van der Greef J, Lafeber FP.

Inflammopharmacology. 2016 Dec;24(6):397-402. Epub 2016 Sep 28.

41.

Rheumatology training experience across Europe: analysis of core competences.

Sivera F, Ramiro S, Cikes N, Cutolo M, Dougados M, Gossec L, Kvien TK, Lundberg IE, Mandl P, Moorthy A, Panchal S, da Silva JA, Bijlsma JW; Working Group on Training in Rheumatology across Europe.

Arthritis Res Ther. 2016 Sep 23;18(1):213. Erratum in: Arthritis Res Ther. 2016 Dec 19;18(1):300.

42.
43.

Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.

Cuppen BV, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen AC, Peeters JJ, Bijlsma JW, Tekstra J, van Laar JM, Hankemeier T, Lafeber FP, van der Greef J; all Society for Rheumatology Research Utrecht investigators.

PLoS One. 2016 Sep 15;11(9):e0163087. doi: 10.1371/journal.pone.0163087. eCollection 2016.

44.

Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients.

Lübbers J, van Beers-Tas MH, Vosslamber S, Turk SA, de Ridder S, Mantel E, Wesseling JG, Reijm M, van Hoogstraten IM, Bijlsma JW, van Schaardenburg D, Bontkes HJ, Verweij CL.

Arthritis Res Ther. 2016 Sep 14;18(1):205. doi: 10.1186/s13075-016-1102-2.

45.

Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?

Cuppen BV, Rossato M, Fritsch-Stork RD, Concepcion AN, Schenk Y, Bijlsma JW, Radstake TR, Lafeber FP; all SRU investigators.

Arthritis Res Ther. 2016 Aug 24;18:189. doi: 10.1186/s13075-016-1085-z.

46.

Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology.

Beyer C, Ramiro S, Sivera F, Mandl P, Machado PM, Ospelt C, Moltó A, Radner H, Iagnocco A, Bijlsma JW, Lundberg IE; EMEUNET country liaisons group .

RMD Open. 2016 Jul 27;2(2):e000240. doi: 10.1136/rmdopen-2015-000240. eCollection 2016.

47.

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.

Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone L, Lu N, Murrell DF, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH.

Ann Rheum Dis. 2017 Mar;76(3):543-546. doi: 10.1136/annrheumdis-2016-210002. Epub 2016 Jul 29.

48.

The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes.

de Jong TD, Lübbers J, Turk S, Vosslamber S, Mantel E, Bontkes HJ, van der Laken CJ, Bijlsma JW, van Schaardenburg D, Verweij CL.

Arthritis Res Ther. 2016 Jul 13;18:165. doi: 10.1186/s13075-016-1065-3.

49.

Expression of ERAP2 and LST1 is increased before start of therapy in rheumatoid arthritis patients with good clinical response to glucocorticoids.

Fritsch-Stork RD, Silva-Cardoso SC, Groot Koerkamp MJ, Broen JC, Lafeber FF, Bijlsma JW.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):685-9. Epub 2016 Jun 22.

PMID:
27384923
50.

[Impaired immunity: risk groups and consequences for general practice].

Opstelten W, Bijlsma JW, Gelinck LB, Hielkema CM, Verheij TJ, van Eden W.

Ned Tijdschr Geneeskd. 2016;160:A9752. Review. Dutch.

PMID:
27299487

Supplemental Content

Loading ...
Support Center